BridgeMD
New treatment option for Type 1 Diabetes
Official title A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar
ClinicalTrials.gov ID: NCT07284511
What this study is testing
What is Tirzepatide?
Tirzepatide is an investigational medicine, given as an once-weekly injection under the skin, being studied as a potential treatment for type 1 diabetes.
Also referred to as Mounjaro.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This research study is testing whether a weekly medication called tirzepatide can help adults with type 1 diabetes use their insulin pump more easily, specifically by reducing or eliminating the need to count carbohydrates at meals. People with type 1 diabetes must take insulin for life, and even with advanced insulin pumps and continuous glucose monitors, many still struggle to keep blood sugar within the target range.
- Phase 3: a large, late-stage study
- Time commitment: about 12 weeks
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years.
- Clinical diagnosis of type 1 diabetes for ≥ 1 year, per investigator judgment (confirmatory C-peptide and autoantibodies not required).
- A BMI ≥ 27 kg/m2.
- HbA1c \> 6.5%, and \< 12%.
- Current therapy: multiple daily injections or insulin pump.
You likely can't join if
- Use of GLP1-RAs within the last four weeks.
- Use of antihyperglycemic agents other than insulin or metformin within the last 2 weeks.
- Planned or ongoing pregnancy.
- Breastfeeding.
- Severe hypoglycemia requiring hospitalization in the past 2 months. Severe hypoglycemia is defined as requiring the assistance of another person, due...
- Diabetic ketoacidosis within the last 2 months.
See the full eligibility criteria
- Age ≥ 18 years.
- Clinical diagnosis of type 1 diabetes for ≥ 1 year, per investigator judgment (confirmatory C-peptide and autoantibodies not required).
- A BMI ≥ 27 kg/m2.
- HbA1c \> 6.5%, and \< 12%.
- Current therapy: multiple daily injections or insulin pump.
- Willingness to use Tandem Control IQ insulin pump system with the use of rapid or ultra rapid-acting insulins compatible with Tandem Control-IQ pump (e.g. Fiasp is not compatible)
- Active carbohydrate counting for prandial insulin dosing.
- Individuals of childbearing potential must be using or agree to use an effective birth-control method. Childbearing potential refers to participants of the female sex post-menarche who have not reached menopause and who...
- Use of GLP1-RAs within the last four weeks.
- Use of antihyperglycemic agents other than insulin or metformin within the last 2 weeks.
- Planned or ongoing pregnancy.
- Breastfeeding.
- Severe hypoglycemia requiring hospitalization in the past 2 months. Severe hypoglycemia is defined as requiring the assistance of another person, due to altered consciousness, to administer carbohydrates, glucagon, or...
- Diabetic ketoacidosis within the last 2 months.
- History of acute or chronic pancreatitis.
- Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2.
- Severe renal impairment with eGFR \<30 mL/min/1.73 m2 (CKD-EPI), measured within the last four months.
- Clinically significant proliferative diabetic retinopathy or gastroparesis, as per the judgment of the investigator.
- Current or ≤ 1 month use of supraphysiological doses of oral or intravenous glucocorticoids.
- History of bariatric surgery within the last 6 months.
- Medical or psychiatric illness likely to interfere with participation (e.g. cirrhosis, active cancer, decompensated schizophrenia), per investigator judgment.
- Inability or unwillingness to comply with safe diabetes management practices, in the view of the investigator.
- Any safety concern that, in the investigator's judgment, precludes participation.
The study team makes the final eligibility decision.
Where it's taking place
- Montreal, Quebec, Canada
- Bern, Switzerland
Compensation & support
A stipend or compensation may be offered.
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 12 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Montreal, Quebec, Canada; Bern, Switzerland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.